Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Korean Circ J. 2012 Mar;42(3):173-83. doi: 10.4070/kcj.2012.42.3.173. Epub 2012 Mar 26.
Implantable cardioverter defibrillator (ICD) therapy is recommended as the primary tool for prevention of sudden cardiac death (SCD) in symptomatic patients with severe left ventricular dysfunction. There is a paucity of information on whether this recommendation is appropriate for the Korean population with severe heart failure.
The study group consisted of 275 consecutive patients (mean age 65 years, 71% male) who met the ICD implantation criteria for primary prevention (left ventricular ejection fraction ≤30% and New York Heart Association functional class II or III). We analyzed the clinical characteristics and outcomes of an ischemic cardiomyopathy (ICMP) group (n=131) and a non-ischemic cardiomyopathy (NICMP) group (n=144). The outcomes of these 2 groups were compared with the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II) conventional and Defibrillators in the Non-ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) standard therapy groups, respectively.
Eighty patients (29%) died during a follow-up period of 40±17 months. The NICMP group had better all-cause mortality rates than the ICMP group (19% vs. 40%, p<0.001), however both groups had a similar incidence of SCD (7% vs. 10%, p=0.272). The 2-year all-cause mortality and SCD for the ICMP group were similar to those of the MADIT-II conventional therapy group (20% vs. 20%, 7% vs. 10%, respectively, all p>0.05). All-cause mortality and the incidence of SCD in the NICMP group were comparable to those of the DEFINITE standard therapy group (13% vs. 17%, 6% vs. 6%, respectively, all p>0.05).
Korean patients with severe heart failure in both the ICMP and NICMP groups had all-caused mortality and risk of SCD comparable to patients in the MADIT-II and DEFINITE standard therapy groups. Therefore, the primary prevention criteria for ICD implantation would be appropriate in both Korean ICMP and NICMP patients.
植入式心脏复律除颤器(ICD)治疗被推荐作为预防有症状的严重左心室功能障碍患者心源性猝死(SCD)的主要手段。目前,关于该推荐是否适用于韩国严重心力衰竭患者,相关信息还很有限。
研究组包括 275 例连续患者(平均年龄 65 岁,71%为男性),他们符合 ICD 植入的一级预防标准(左心室射血分数≤30%,纽约心脏协会功能分级 II 或 III 级)。我们分析了缺血性心肌病(ICMP)组(n=131)和非缺血性心肌病(NICMP)组(n=144)的临床特征和结局。这两组的结果分别与多中心自动除颤器植入试验 II(MADIT-II)常规治疗组和非缺血性心肌病治疗评估的除颤器(DEFINITE)标准治疗组进行了比较。
在 40±17 个月的随访期间,有 80 例(29%)患者死亡。NICMP 组的全因死亡率优于 ICMP 组(19%比 40%,p<0.001),但两组的 SCD 发生率相似(7%比 10%,p=0.272)。ICMP 组的 2 年全因死亡率和 SCD 与 MADIT-II 常规治疗组相似(20%比 20%,7%比 10%,均 p>0.05)。NICMP 组的全因死亡率和 SCD 发生率与 DEFINITE 标准治疗组相当(13%比 17%,6%比 6%,均 p>0.05)。
韩国严重心力衰竭的 ICMP 和 NICMP 患者的全因死亡率和 SCD 风险与 MADIT-II 和 DEFINITE 标准治疗组患者相似。因此,ICD 植入的一级预防标准适用于韩国的 ICMP 和 NICMP 患者。